Dr Mairi Gael Leining, MD | |
900 Round Valley Dr, Park City, UT 84060-7552 | |
(435) 658-7000 | |
(530) 541-8723 |
Full Name | Dr Mairi Gael Leining |
---|---|
Gender | Female |
Speciality | Hospitalist |
Location | 900 Round Valley Dr, Park City, Utah |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1629066469 | NPI | - | NPPES |
00A924960 | Medicaid | CA | |
100510444 | Medicaid | NV |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207R00000X | Internal Medicine | A92496 (California) | Secondary |
208M00000X | Hospitalist | 7744218-1205 (Utah) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Mairi Gael Leining, MD Po Box 27128, Salt Lake City, UT 84127-0128 Ph: (435) 658-7000 | Dr Mairi Gael Leining, MD 900 Round Valley Dr, Park City, UT 84060-7552 Ph: (435) 658-7000 |
News Archive
The hippocampus is a brain structure that plays a major role in the process of memory formation. It is not entirely clear how the hippocampus manages to string together events that are part of the same experience but are separated by "empty" periods of time. Now, new research published by Cell Press in the August 25 issue of the journal Neuron finds that there are neurons in the hippocampus that encode every sequential moment in a series of events that compose a discrete experience.
By developing a new way to compare techniques for teaching robotic surgery, doctors at The Methodist Hospital and the University of Southern California report in an upcoming issue of the British Journal of Urology International that surgeons training in robotic surgery learned best when three different teaching methods were used.
In a recent Journal of Sleep Research study, participants perceived pleasant and neutral pictures in a more negative way when their sleep was restricted for several nights in a row.
BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.
› Verified 9 days ago